Article Text

PDF
A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease
  1. H Tsukamoto1,
  2. K Nagafuji1,
  3. T Horiuchi1,
  4. T Miyamoto1,
  5. K Aoki1,
  6. K Takase1,
  7. H Henzan1,
  8. D Himeji1,
  9. T Koyama1,
  10. K Miyake1,
  11. Y Inoue1,
  12. H Nakashima1,
  13. T Otsuka1,
  14. Y Tanaka2,
  15. K Nagasawa3,
  16. M Harada1
  1. 1Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
  2. 2First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Kitakyushu 807-8555, Japan
  3. 3Division of Rheumatology, Saga Medical School, 5-1-1 Nabeshima, Saga, 849-8501, Japan
  1. Correspondence to:
    Dr H Tsukamoto
    Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan; tsukamot{at}intmed1.med.kyushu-u.ac.jp

Abstract

Objectives: To carry out a phase I-II trial to elucidate the feasibility and efficacy of high dose cyclophosphamide (CY) supported by autologous peripheral blood stem cell transplantation (PBSCT) in the treatment of severe and refractory autoimmune disease (AD).

Methods: Peripheral blood stem cells (PBSCs) were mobilised during haematological recovery after relatively high dose CY (2 g/m2) for 2 days, followed by administration of granulocyte colony stimulating factor. After collecting PBSCs—more than 2×106 CD34+ cells/kg—by apheresis, CD34+ cells were immunologically selected and cryopreserved. Eight patients were enrolled—five had systemic sclerosis (SSc) alone, one had SSc with systemic lupus erythematosus, one amyopathic dermatomyositis (ADM), and one Wegener’s granulomatosis (WG). All of the patients were treated with high dose CY (50 mg/kg) for 4 days and autologous PBSCT.

Results: Haematopoietic reconstitution was rapid and sustained. Toxicity due to the regimen included various infections such as pneumonia, sepsis, cystitis, herpes zoster, and acute heart failure. However, there was no treatment related mortality. Encouraging results were obtained after autologous PBSCT. Sclerosis of the skin was markedly improved in all of the patients with SSc. Interstitial pneumonia (IP), evaluated by Pao2, serum KL-6 levels, and pulmonary high resolution computed tomography, improved significantly. In a patient with ADM, severe and progressive IP also improved markedly. In a patient with WG, the size of the left orbital granuloma decreased substantially, resulting in reduction of the exophthalmos.

Conclusions: These observations suggest that high dose CY with autologous PBSCT is feasible and may be effective in the treatment of severe and refractory AD.

  • A-aDo2, alveolar-arterial oxygen tension difference
  • AD, autoimmune disease
  • ADM, amyopathic dermatomyositis
  • ATG, antithymocyte globulin
  • CY, cyclophosphamide
  • HRCT, high resolution computed tomography
  • G-CSF, granulocyte-colony stimulating factor
  • HSCT, haematopoietic stem cell transplantation
  • IP, interstitial pneumonia
  • mRSS, modified Rodnan skin score
  • NHL, non-Hodgkin’s lymphoma
  • NIH-CTC, National Cancer Institute-Common Toxicity Criteria
  • Pao2, arterial oxygen pressure
  • PBSCs, peripheral blood stem cells
  • PBSCT, peripheral blood stem cell transplantation
  • SSc, systemic sclerosis
  • TBI, total body irradiation
  • Tlco, carbon monoxide transfer factor
  • TRM, treatment related mortality
  • VC, vital capacity
  • WG, Wegener’s granulomatosis
  • autoimmune disease
  • high dose cyclophosphamide
  • interstitial pneumonia
  • transplantation
  • Wegener’s granulomatosis

Statistics from Altmetric.com

Footnotes

  • Published Online First 26 August 2005

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.